Quinsair is an inhaled formulation of the antibiotic levofloxacin that is approved in the EU for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis. It is marketed in the EU as an oral solution for inhalation via nebulization, and is the only approved inhaled fluoroquinolone therapy for cystic fibrosis patients. Quinsair was first launched in Germany in April 2016 and is subsequently being rolled out throughout the rest of the EU.
LIST OF FIGURES
9 Figure 1: Quinsair for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Quinsair for cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Quinsair for cystic fibrosis
13 Figure 4: Quinsair sales for cystic fibrosis across the five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Quinsair drug profile
7 Table 2: Quinsair Phase IIb/III data in cystic fibrosis
14 Table 3: Quinsair sales for cystic fibrosis across the five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.